MedTrace Logo

Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children

NCT04996485 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-08-09

No results posted yet for this study

Summary

This is an experimental non-randomized clinical study aimed at expanding the indications for the use of biological drugs with the aim of using them for the pathogenetic therapy of children with congenital ichthyosis.

Conditions

  • Congenital Ichthyosis

Interventions

DRUG

Secukinumab Injection

Pathogenetic therapy with biologic drugs

DRUG

Ustekinumab Injection

Pathogenetic therapy with biologic drugs

DRUG

Dupilumab Injection

Pathogenetic therapy with biologic drugs

OTHER

Symptomatic therapy

Active external agents, Emollients, systemic retinoids if needed

Sponsors & Collaborators

  • National Medical Research Center for Children's Health, Russian Federation

    lead OTHER_GOV

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2023-03-01
Completion
2023-06-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04996485 on ClinicalTrials.gov